Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-55885
Mol Pharmacol 2018 Oct 01;944:1155-1163. doi: 10.1124/mol.118.112953.
Show Gene links Show Anatomy links

Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels.

Manville RW , Abbott GW .


???displayArticle.abstract???
Synthetic gabapentinoids, exemplified by gapapentin and pregabalin, are in extensive clinical use for indications including epilepsy, neuropathic pain, anxiety, and alcohol withdrawal. Their mechanisms of action are incompletely understood, but are thought to involve inhibition of α2δ subunit-containing voltage-gated calcium channels. Here, we report that gabapentin is a potent activator of the heteromeric KCNQ2/3 voltage-gated potassium channel, the primary molecular correlate of the neuronal M-current, and also homomeric KCNQ3 and KCNQ5 channels. In contrast, the structurally related gabapentinoid, pregabalin, does not activate KCNQ2/3, and at higher concentrations (≥10 µM) is inhibitory. Gabapentin activation of KCNQ2/3 (EC50 = 4.2 nM) or homomeric KCNQ3* (EC50 = 5.3 nM) channels requires KCNQ3-W265, a conserved tryptophan in KCNQ3 transmembrane segment 5. Homomeric KCNQ2 or KCNQ4 channels are insensitive to gabapentin, whereas KCNQ5 is highly sensitive (EC50 = 1.9 nM). Given the potent effects and the known anticonvulsant, antinociceptive, and anxiolytic effects of M-channel activation, our findings suggest the possibility of an unexpected role for M-channel activation in the mechanism of action of gabapentin.

???displayArticle.pubmedLink??? 30021858
???displayArticle.pmcLink??? PMC6108572
???displayArticle.link??? Mol Pharmacol
???displayArticle.grants??? [+]

Species referenced: Xenopus laevis
Genes referenced: kcnq1 kcnq2 kcnq3 kcnq4 kcnq5
GO keywords: voltage-gated potassium channel activity

References [+] :
Alles, Etiology and Pharmacology of Neuropathic Pain. 2018, Pubmed